Rebound insomnia after hypnotic withdrawal in insomniac outpatients
Abstract
The effect of abrupt medication withdrawal (no-pill discontinuation) was investigated in 1507 insomniacs using the patients' self-ratings on visual analogue scales. Drug discontinuation followed a 28-day treatment period with either 7.5 mg zopiclone, 0.25 mg triazolam, 1.0 mg flunitrazepam, or placebo in a randomized, double-blind, parallel group, multicenter study in private practice. Deterioration below individual pretreatment values (no-pill baseline) in at least one of three subjective parameters of sleep quality (sleep latency, total sleep time, nocturnal awakenings) and three parameters of daytime well-being (morning freshness, daytime tiredness, anxiety) were defined as rebound. The number of patients with rebound (rebound rate) was analyzed for every day of a 2-week posttreatment period. The overall rebound rate was higher in the placebo group (p < or = 0.001) than in each group treated with active drugs. Rebound rates affecting sleep quality were higher for placebo than for zopiclone (p < or = 0.001) and for flunitrazepam (p < or = 0.05). Rebound rates were smaller for zopiclone (p < or = 0.001) and flunitrazepam (p < or = 0.01) than for triazolam. Rebound in at least one item per day appeared in 21.5% (sleep quality) and 25.5% (daytime well-being) of the patients. Rebound decreased with increasing numbers of items of sleep quality or daytime well-being. Patients who did not respond to treatment showed higher rebound rates than those who were treatment responders (p < or = 0.001). Concerning treatment nonresponders, highest rebound was seen in the placebo group, whereas rebound was lowest in placebo responders. These results show that pill discontinuation itself may worsen sleep and daytime well-being in the sense of a rebound phenomenon. Furthermore, the number of patients with rebound remained at a high and varying level during the whole posttreatment period. This result indicates that a deterioration of sleep after drug withdrawal is not apparent during a few days but may last for longer periods in some patients and is modified by marked night-to-night variations.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Rebound anxiety was observed following benzodiazepine withdrawal.
“Rebound anxiety was also observed [1, 38, 50].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [50]
After discontinuation of rapidly eliminated benzodiazepines (lorazepam, oxazepam), new withdrawal symptoms occurred within 48 h.
“after discontinuation of rapidly eliminated benzodiazepines (i.e., lorazepam, oxazepam) [50], new withdrawal symptoms occurred within 48 h”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [50]
The citation lists haven’t been fetched yet
References 36 · Cited by 39
- Authors
- Hajak, G., Clarenbach, P., Fischer, W., Rodenbeck, A., Bandelow, B., Broocks, A., & Rüther, E.
- Affiliations
- University of Göttingen (DE)
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 1998-07-28
- Volume
- 248
- Issue
- 3
- Pages
- 148-156
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- OpenAlex
- W2009316739
- Cited by
- 39
- References
- 36
- Citations by year
- 2023: 3 · 2022: 2 · 2021: 1 · 2020: 1 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 3 · 2012: 3
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Physiology › Obstructive Sleep Apnea Research
- Keywords
- rebound insomnia, hypnotic withdrawal, insomnia, zopiclone, triazolam, flunitrazepam, benzodiazepines, sleep quality, treatment non-responders, outpatients
- MeSH terms
- Adolescent, Adult, Aged, Analysis of Variance, Double-Blind Method, Drug Administration Schedule, Female, Flunitrazepam, Humans, Hypnotics and Sedatives, Sleep Initiation and Maintenance Disorders, Male, Middle Aged, Piperazines, Placebos, Recurrence, Sleep, Anti-Anxiety Agents, Triazolam, Treatment Outcome, Azabicyclo Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review